Description of the drug
RYDAPT / RIDAPT (Midostaurin) from Novartis is a medicinal product used in hematology. The drug is available in tablet form with a dosage of 25 mg. Midostaurin is the chemical name of the drug, which has the commercial name Rydapt.
Indications for use
RYDAPT is prescribed for the treatment of certain types of hematological disorders. It can be used for patients with certain forms of blood cancer or an increased risk of developing blood disorders.
Advantages
- Effectiveness in the treatment of hematological disorders
- Convenience of use in tablet form
- Well-known manufacturer Novartis
Application
RYDAPT should be taken as prescribed by a doctor. Usually, the dosage regimen is established individually depending on the patient and the nature of the disease.
Who is it suitable for
The drug Rydapt is intended for adult patients with hematological disorders or at risk of developing them.
Search queries
This drug is also searched for as: Mitikaid, Midostaurin, Rydapt 25 mg